NASDAQ:HSGXHistogenics Stock Price, Forecast & News

$0.32

-0.01 (-3.00 %)

(As of 05/28/2020 12:35 PM ET)

Add

Compare

Today's Range

$0.31

Now: $0.32▼

$0.34

50-Day Range

$0.26

MA: $0.33▼

$0.47

52-Week Range

$0.08

Now: $0.32▼

$1.43

Volume10.96 million shs

Average Volume10.71 million shs

Market Capitalization$30.56 million

P/E RatioN/A

Dividend YieldN/A

Beta3.1

Histogenics Corporation develops restorative cell therapies that would offer rapid-onset pain relief and restored function. The company was founded in 2000 and is headquartered in Waltham, Massachusetts.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Histogenics.

2.8 Community Rank

Outperform Votes
Histogenics has received 359 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Histogenics has received 284 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Histogenics has received 55.83% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Histogenics and other stocks. Vote “Outperform” if you believe HSGX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HSGX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Histogenics does not currently pay a dividend.
Dividend Growth
Histogenics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Histogenics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 19.70% of the stock of Histogenics is held by insiders.
Percentage Held by Institutions
40.35% of the stock of Histogenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Histogenics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Histogenics is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

0.76 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Surgical appliances & supplies

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HSGX

Previous Symbol

CUSIPN/A

CIK1372299

Webwww.histogenics.com

Phone781-547-7900

Debt

Debt-to-Equity RatioN/A

Current Ratio4.05

Quick Ratio4.05

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value($0.01) per share

Price / Book-32.30

Profitability

EPS (Most Recent Fiscal Year)($0.79)

Net Income$-8,640,000.00

Net MarginsN/A

Return on Equity-34.96%

Return on Assets18.40%

Miscellaneous

Employees49

Outstanding Shares94,600,000

Market Cap$30.56 million

Next Earnings Date8/7/2020 (Estimated)

OptionableNot Optionable

Receive HSGX News and Ratings via Email

Sign-up to receive the latest news and ratings for HSGX and its competitors with MarketBeat's FREE daily newsletter.

Histogenics (NASDAQ:HSGX) Frequently Asked Questions

How has Histogenics' stock been impacted by COVID-19 (Coronavirus)?

Histogenics' stock was trading at $0.40 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, HSGX shares have decreased by 19.3% and is now trading at $0.3230. View which stocks have been most impacted by Coronavirus.

When is Histogenics' next earnings date?

Histogenics is scheduled to release its next quarterly earnings announcement on Friday, August 7th 2020. View our earnings forecast for Histogenics.

How were Histogenics' earnings last quarter?

Histogenics Corp (NASDAQ:HSGX) released its earnings results on Thursday, August, 9th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.10. View Histogenics' earnings history.

Has Histogenics been receiving favorable news coverage?

News stories about HSGX stock have trended somewhat negative this week, according to InfoTrie. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Histogenics earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutHistogenics.

Who are some of Histogenics' key competitors?

Some companies that are related to Histogenics include Lakeland Industries (LAKE), ConforMIS (CFMS), COLLPLANT HOLDI/S (CLGN), Allied Healthcare Products (AHPI), Ocugen (OCGN), Precision Therapeutics (POAI), Rewalk Robotics (RWLK), Bionik Laboratories (BNKL), NanoVibronix (NAOV) and Avitar (AVTI). View all competitors.

What other stocks do shareholders of Histogenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Histogenics investors own include Interpace Diagnostics Group (IDXG), Novavax (NVAX), Verastem (VSTM), Progenics Pharmaceuticals (PGNX), SCYNEXIS (SCYX), Magnegas Applied Tchnlgy Sltns (MNGA), Trevena (TRVN), Ocular Therapeutix (OCUL), Opko Health (OPK) and Synergy Pharmaceuticals (SGYP).

Who are Histogenics' key executives?

Histogenics' management team includes the following people:

Mr. Adam D. Gridley, Interim Pres, CEO Treasurer, Sec., Consultant & Director (Age 47)
Mr. Jonathan I. Lieber, Interim Chief Financial Officer (Age 49)
Mr. Stephen R. Kennedy, Consultant (Age 62)

When did Histogenics IPO?

(HSGX) raised $60 million in an IPO on Wednesday, December 3rd 2014. The company issued 4,300,000 shares at a price of $13.00-$15.00 per share. Cowen and Company, Needham & Company and Canaccord Genuity served as the underwriters for the IPO and BTIG was co-manager.

What is Histogenics' stock symbol?

Histogenics trades on the NASDAQ under the ticker symbol "HSGX."

How do I buy shares of Histogenics?

Shares of HSGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Histogenics' stock price today?

One share of HSGX stock can currently be purchased for approximately $0.32.

How big of a company is Histogenics?

Histogenics has a market capitalization of $30.56 million. The biotechnology company earns $-8,640,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis. Histogenics employs 49 workers across the globe.

What is Histogenics' official website?

The official website for Histogenics is www.histogenics.com.

How can I contact Histogenics?

Histogenics' mailing address is 830 WINTER STREET 3RD FLOOR, WALTHAM MA, 02451. The biotechnology company can be reached via phone at 781-547-7900 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff